ATE543833T1 - Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen - Google Patents

Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen

Info

Publication number
ATE543833T1
ATE543833T1 AT06849993T AT06849993T ATE543833T1 AT E543833 T1 ATE543833 T1 AT E543833T1 AT 06849993 T AT06849993 T AT 06849993T AT 06849993 T AT06849993 T AT 06849993T AT E543833 T1 ATE543833 T1 AT E543833T1
Authority
AT
Austria
Prior art keywords
methods
bmp
variant compositions
peptide chains
variant
Prior art date
Application number
AT06849993T
Other languages
English (en)
Inventor
Bernard Amegadzie
Mark R Cunningham
Jeffrey Luo
Juliane Mills
Bethany Swencki-Underwood
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of ATE543833T1 publication Critical patent/ATE543833T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06849993T 2005-12-22 2006-12-20 Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen ATE543833T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75296905P 2005-12-22 2005-12-22
PCT/US2006/048730 WO2007087053A2 (en) 2005-12-22 2006-12-20 Bmp-7 variant compositions, methods and uses

Publications (1)

Publication Number Publication Date
ATE543833T1 true ATE543833T1 (de) 2012-02-15

Family

ID=38309705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06849993T ATE543833T1 (de) 2005-12-22 2006-12-20 Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen

Country Status (4)

Country Link
EP (1) EP1978994B1 (de)
JP (1) JP5100662B2 (de)
AT (1) ATE543833T1 (de)
WO (1) WO2007087053A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
JP2009544325A (ja) * 2006-07-27 2009-12-17 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
ES2447516T3 (es) 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
US7846428B2 (en) * 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
JP5819734B2 (ja) 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
CA2752157A1 (en) 2009-02-12 2010-08-19 Stryker Corporation Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease
US20120148539A1 (en) 2009-03-24 2012-06-14 Moulay Hicham Alaoui-Ismaili Methods and Compositions for Tissue Engineering
WO2011031856A1 (en) 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
ES2387379T3 (es) 2009-09-17 2012-09-21 Stryker Corporation Tampones para controlar el pH de las proteínas morfogenéticas óseas
AU2010341565A1 (en) 2009-12-22 2012-07-12 Stryker Corporation BMP-7 variants with reduced immunogenicity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919308B2 (en) * 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
CA2141555C (en) * 1992-07-31 2007-03-27 Stryker Corporation Morphogenic protein soluble complex and composition thereof
ATE364629T1 (de) * 1996-01-22 2007-07-15 Curis Inc Methoden zur herstellung von op-1 morphogen analoge
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6846906B1 (en) * 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体

Also Published As

Publication number Publication date
JP2009521220A (ja) 2009-06-04
WO2007087053A2 (en) 2007-08-02
JP5100662B2 (ja) 2012-12-19
WO2007087053A3 (en) 2008-10-16
EP1978994B1 (de) 2012-02-01
EP1978994A2 (de) 2008-10-15
EP1978994A4 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
BR0211986A (pt) 29-enóis de rapamicina
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60329983D1 (de) Wachsestersynthase-dna-sequenz, protein und verwendungen davon
DE602005012555D1 (de) Künstliches protein zur absoluten quantifizierung von proteinen und verwendungen davon
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE50305507D1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
DE60334839D1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
WO2008014054A3 (en) Bmp-7 variant compositions, methods and uses
WO2006047728A3 (en) Bmp gene and fusion protein
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
JO3046B1 (ar) اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها.
ATE420162T1 (de) Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen
ATE505538T1 (de) Dna-vektoren
ATE526400T1 (de) Metalloproteaseproteine
ATE485831T1 (de) Behandlung von neurodegeneration
GB0520872D0 (en) Onion flavour compounds and use
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
MY142798A (en) Methods for preventing glyconoylation of proteins